A year ago, they were trading at $1.04. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS
Vivus’s Qnexa, the first of three new anti-obesity drugs under FDA review this year, came before one of the agency’s advisory committees today — and it was a swing and a miss. The panel recommended against …
If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com Cambridge, …
If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com Cambridge, …